These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

572 related articles for article (PubMed ID: 31477544)

  • 21. Prevention of violence against women and girls: A cost-effectiveness study across 6 low- and middle-income countries.
    Ferrari G; Torres-Rueda S; Chirwa E; Gibbs A; Orangi S; Barasa E; Tawiah T; Dwommoh Prah RK; Hitimana R; Daviaud E; Kapapa E; Dunkle K; Heise L; Stern E; Chatterji S; Omondi B; Ogum Alangea D; Karmaliani R; Maqbool Ahmed Khuwaja H; Jewkes R; Watts C; Vassall A
    PLoS Med; 2022 Mar; 19(3):e1003827. PubMed ID: 35324910
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cost effectiveness of strategies to combat cardiovascular disease, diabetes, and tobacco use in sub-Saharan Africa and South East Asia: mathematical modelling study.
    Ortegón M; Lim S; Chisholm D; Mendis S
    BMJ; 2012 Mar; 344():e607. PubMed ID: 22389337
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Polypill Programs to Prevent Stroke and Cut Costs in Low Income Countries: Moving From Clinical Efficacy to Pragmatic Implementation.
    Sarfo FS; Nichols M; Opare-Addo PA; Ovbiagele B
    Stroke; 2023 Feb; 54(2):407-414. PubMed ID: 36689592
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Investing in late-stage clinical trials and manufacturing of product candidates for five major infectious diseases: a modelling study of the benefits and costs of investment in three middle-income countries.
    Schäferhoff M; Zimmerman A; Diab MM; Mao W; Chowdhary V; Gill D; Karanja R; Madikizela M; Ogbuoji O; Yamey G
    Lancet Glob Health; 2022 Jul; 10(7):e1045-e1052. PubMed ID: 35714631
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cost-effectiveness of HIV treatment as prevention in serodiscordant couples.
    Walensky RP; Ross EL; Kumarasamy N; Wood R; Noubary F; Paltiel AD; Nakamura YM; Godbole SV; Panchia R; Sanne I; Weinstein MC; Losina E; Mayer KH; Chen YQ; Wang L; McCauley M; Gamble T; Seage GR; Cohen MS; Freedberg KA
    N Engl J Med; 2013 Oct; 369(18):1715-25. PubMed ID: 24171517
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Estimating a cost-effectiveness threshold for health care decision-making in South Africa.
    Edoka IP; Stacey NK
    Health Policy Plan; 2020 Jun; 35(5):546-555. PubMed ID: 32125375
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cost-effectiveness of community mobilization (Camino Verde) for dengue prevention in Nicaragua and Mexico: A cluster randomized controlled trial.
    Tschampl CA; Undurraga EA; Ledogar RJ; Coloma J; Legorreta-Soberanis J; Paredes-Solís S; Arosteguí J; Hernández-Álvarez C; Harris E; Andersson N; Shepard DS
    Int J Infect Dis; 2020 May; 94():59-67. PubMed ID: 32179138
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Novel Treatment Strategies for Secondary Prevention of Cardiovascular Disease: A Systematic Review of Cost-Effectiveness.
    Marquina C; Zomer E; Vargas-Torres S; Zoungas S; Ofori-Asenso R; Liew D; Ademi Z
    Pharmacoeconomics; 2020 Oct; 38(10):1095-1113. PubMed ID: 32583316
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cost-effectiveness of fixed-dose combination pill (Polypill) in primary and secondary prevention of cardiovascular disease: A systematic literature review.
    Jahangiri R; Rezapour A; Malekzadeh R; Olyaeemanesh A; Roshandel G; Motevalian SA
    PLoS One; 2022; 17(7):e0271908. PubMed ID: 35901100
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Generalized Cost-Effectiveness Analysis of Pharmaceutical Interventions for Primary Prevention of Cardiovascular Disease in Thailand.
    Khonputsa P; Veerman LJ; Bertram M; Lim SS; Chaiyakunnaphruk N; Vos T
    Value Health Reg Issues; 2012 May; 1(1):15-22. PubMed ID: 29702820
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cost-effectiveness of medical primary prevention strategies to reduce absolute risk of cardiovascular disease in Tanzania: a Markov modelling study.
    Ngalesoni FN; Ruhago GM; Mori AT; Robberstad B; Norheim OF
    BMC Health Serv Res; 2016 May; 16():185. PubMed ID: 27184802
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cost-effectiveness of group medical visits and microfinance interventions versus usual care to manage hypertension in Kenya: a secondary modelling analysis of data from the Bridging Income Generation with Group Integrated Care (BIGPIC) trial.
    Chay J; Su RJ; Kamano JH; Andama B; Bloomfield GS; Delong AK; Horowitz CR; Menya D; Mugo R; Orango V; Pastakia SD; Wanyonyi C; Vedanthan R; Finkelstein EA
    Lancet Glob Health; 2024 Aug; 12(8):e1331-e1342. PubMed ID: 39030063
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A cardiovascular polypill for secondary stroke prevention in a tertiary centre in Ghana (SMAART): a phase 2 randomised clinical trial.
    Sarfo FS; Voeks J; Adamu S; Agyei BA; Agbenorku M; Adu-Darko N; Oteng MA; Obese V; Gyamfi RA; Mensah NA; Tagge R; Ampofo M; Kontoh SA; Nguah SB; Ovbiagele B
    Lancet Glob Health; 2023 Oct; 11(10):e1619-e1628. PubMed ID: 37734804
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cost-effectiveness of two versus three or more doses of intermittent preventive treatment for malaria during pregnancy in sub-Saharan Africa: a modelling study of meta-analysis and cost data.
    Fernandes S; Sicuri E; Kayentao K; van Eijk AM; Hill J; Webster J; Were V; Akazili J; Madanitsa M; ter Kuile FO; Hanson K
    Lancet Glob Health; 2015 Mar; 3(3):e143-53. PubMed ID: 25701992
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cost-benefit analysis of the polypill in the primary prevention of myocardial infarction and stroke.
    Wald NJ; Luteijn JM; Morris JK; Taylor D; Oppenheimer P
    Eur J Epidemiol; 2016 Apr; 31(4):415-26. PubMed ID: 26946426
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A systematic review and economic evaluation of statins for the prevention of coronary events.
    Ward S; Lloyd Jones M; Pandor A; Holmes M; Ara R; Ryan A; Yeo W; Payne N
    Health Technol Assess; 2007 Apr; 11(14):1-160, iii-iv. PubMed ID: 17408535
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treat All versus targeted strategies to select HBV-infected people for antiviral therapy in The Gambia, west Africa: a cost-effectiveness analysis.
    Nguyen LBL; Lemoine M; Ndow G; Ward ZJ; Hallet TB; D'Alessandro U; Thursz M; Nayagam S; Shimakawa Y
    Lancet Glob Health; 2024 Jan; 12(1):e66-e78. PubMed ID: 38097300
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Availability and affordability of cardiovascular disease medicines and their effect on use in high-income, middle-income, and low-income countries: an analysis of the PURE study data.
    Khatib R; McKee M; Shannon H; Chow C; Rangarajan S; Teo K; Wei L; Mony P; Mohan V; Gupta R; Kumar R; Vijayakumar K; Lear SA; Diaz R; Avezum A; Lopez-Jaramillo P; Lanas F; Yusoff K; Ismail N; Kazmi K; Rahman O; Rosengren A; Monsef N; Kelishadi R; Kruger A; Puoane T; Szuba A; Chifamba J; Temizhan A; Dagenais G; Gafni A; Yusuf S;
    Lancet; 2016 Jan; 387(10013):61-9. PubMed ID: 26498706
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cost-effectiveness of 10-Year Risk Thresholds for Initiation of Statin Therapy for Primary Prevention of Cardiovascular Disease.
    Pandya A; Sy S; Cho S; Weinstein MC; Gaziano TA
    JAMA; 2015 Jul; 314(2):142-50. PubMed ID: 26172894
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 29.